BIOPOR Bioporto A/S

Managers’ transactions

Managers’ transactions

January 21, 2021

Announcement no. 1

Managers’ transactions

BioPorto has received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transactions related to shares in BioPorto A/S made by persons discharging managerial responsibilities in BioPorto A/S and/or persons closely related with them. BioPorto has been notified that the transaction is carried out for the purpose of settling tax liabilities arising out of returns on BioPorto shares held as pension scheme assets.

1. Details of the person discharging managerial responsibilities/person closely associated 
a) NameThomas Magnussen
2. Reason for the notification 
a) Position/statusChairman of the Board of Directors of BioPorto A/S
b) Initial notification/amendmentInitial notification
3. Details of the issuer 
a) NameBioPorto A/S
b) LEI5299004SWFL5JAN4W830
4. Details of the transaction(s) 
a) Description of the financial instrument, type



of instrument







Identification code
Shares



 





ISIN code DKDK0011048619
b) Nature of the transactionShare sale
c) Price(s) and volume(s)Price: DKK 6.14, Volume: 40,000
d) Aggregated information



  • Aggregated volume



  • Aggregated price
N/A
e) Date of the transaction2021-01-18
f) Place of the transactionNasdaq Copenhagen A/S, XCSE

For further information, please contact:

Ole Larsen, CFO

Telephone , e-mail:

About BioPorto

BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].

Attachment



EN
21/01/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bioporto A/S

 PRESS RELEASE

US News & World Report-webinaret “New Frontiers in Kidney Care” fremhæ...

US News & World Report-webinaret “New Frontiers in Kidney Care” fremhæver NGAL-biomarkøren 11. september, 2025Meddelelse US News & World Report-webinaret “New Frontiers in Kidney Care” fremhæver NGAL-biomarkøren KØBENHAVN, DANMARK og BOSTON, MA, USA, 11. september – BioPorto A/S (BioPorto eller Selskabet) (CPH:BIOPOR) annoncerer det kommende virtuelle arrangement fra US News & World Report: “New Frontiers in Kidney Care”, som vil fokusere på akut og kronisk nyresygdom globalt samt de tiltag, der kan sikre de bedst mulige behandlingsresultater inden for nyresundhed. Webinaret afholdes tors...

 PRESS RELEASE

US News & World Report Webinar “New Frontiers in Kidney Care” features...

US News & World Report Webinar “New Frontiers in Kidney Care” features NGAL biomarker September 11, 2025News Release US News & World Report Webinar “New Frontiers in Kidney Care” features NGAL biomarker COPENHAGEN, DENMARK and BOSTON, MA, USA, September 11 – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), is pleased to announce the upcoming US News & World Report live virtual event "New Frontiers in Kidney Care” which will focus on acute and chronic kidney disease globally and actions that can be taken to ensure best possible outcomes in kidney care. The program will run live on ...

 PRESS RELEASE

Tildeling af Warrants

Tildeling af Warrants 1. september 2025 Meddelelse nr. 20                                                                          Tildeling af Warrants København, Danmark, den 1. september 2025 (GLOBE NEWSWIRE) – Bestyrelsen for BioPorto A/S ("BioPorto" eller "Selskabet") (CPH:BIOPOR) har i dag besluttet at udstede i alt 5.000.000 warrants til et medlem af Selskabets direktion. Hver warrant giver indehaveren ret til at tegne én aktie i BioPorto til en udnyttelseskurs på 1,28 kr. pr. aktie, svarende til lukkekursen på Nasdaq Copenhagen i dag. Warrants udstedes i henhold til § 18 a i S...

 PRESS RELEASE

Grant of Warrants

Grant of Warrants September 1, 2025 Announcement no. 20                                                                          Grant of Warrants Copenhagen, Denmark, September 1, 2025, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has today decided to issue a total of 5,000,000 warrants to a member of the Executive Management. Each warrant entitles the holder the right to subscribe for one share in BioPorto at an exercise price of DKK 1.28 per share, corresponding to the closing price today on Nasdaq Copenhagen. The warrants are...

 PRESS RELEASE

ProNephro AKI™ (NGAL), til tidlig diagnosticering af akut nyreskade, e...

ProNephro AKI™ (NGAL), til tidlig diagnosticering af akut nyreskade, er nu kommercielt tilgængelig på laboratorier i USA gennem BioPortos samarbejde med Roche Diagnostics. 28. august 2025Meddelelse ProNephro AKI™ (NGAL), til tidlig diagnosticering af akut nyreskade, er nu kommercielt tilgængelig på laboratorier i USA gennem BioPortos samarbejde med Roche Diagnostics. Samarbejdet med Roche Diagnostics markerer det første væsentlige kommercielle skridt til at fremme udbredelsen af ProNephro AKI på tværs af hospitaler i USA. KØBENHAVN, DANMARK og BOSTON, MA, USA, 28. august – BioPorto A/S (...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch